Clinical trials: Stage IIIA Breast Cancer
Breast Cancer, Vaginal Dryness
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with…
- Trial name
- NCT00343382
- Testing
- pilocarpine hydrochloride
- Where
- 192 sites in United States
- Volunteers
- 201 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
B-Cell Neoplasm, Estrogen Receptor Negative
18F-FSPG PET/CT for Cancer Patients on Therapy
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic…
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer
- Trial name
- NCT02599194
- Testing
- 18F-FSPG, 18F-FDG
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Andrei Iagaru
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen…
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT02003209
- Testing
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00323063
- Testing
- gemcitabine hydrochloride, imatinib mesylate
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Rutgers, The State University of New Jersey
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Stage II Breast Cancer, Stage IIIA Breast Cancer
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
This phase II trial studies how well trastuzumab and pertuzumab or bevacizumab with combination chemotherapy works in treating patients with stage II-III breast cancer.
- Conditions
- Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01959490
- Testing
- trastuzumab, Pertuzumab, docetaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Radiation Toxicity, Recurrent Breast Cancer
Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
This phase II trial is studying how well alkaline water works in reducing skin toxicity in women with breast cancer undergoing radiation therapy.
- Conditions
- Radiation Toxicity, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01487954
- Testing
- alkaline water, distilled water, external beam radiation therapy (EBRT)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the…
- Trial name
- e3 (NCT01674140)
- Testing
- anastrozole, everolimus, exemestane
- Where
- 1,458 sites in United States, Puerto Rico
- Volunteers
- 1,939 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, HER2-negative Breast Cancer
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
This phase II is studying the side effects and how well carboplatin and paclitaxel albumin-stabilized nanoparticle formulation when together with bevacizumab or trastuzumab before surgery works in treating patients with stage…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00618657
- Testing
- Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of California, Irvine
Breast Cancer
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00847171
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01368263
- Testing
- goserelin acetate, letrozole, anastrozole
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy.
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03872388
- Testing
- Atorvastatin, Capecitabine
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Estrogen Receptor Negative, HER2/Neu Negative
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT02445391
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 1,024 sites in United States, South Africa
- Volunteers
- 415 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Breast Cancer
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy.
- Trial name
- NCT00343512
- Testing
- docetaxel, protein expression analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00820872
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 136 sites in United States
- Volunteers
- 30 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00331630
- Testing
- lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University